The co-crystal approach to improve the exposure of a water-insoluble compound: AMG 517 sorbic acid co-crystal characterization and pharmacokinetics.

Co-crystals are relatively novel in the pharmaceutical field and are not reported extensively. AMG 517 is an insoluble small molecule VR1 (vanilloid receptor 1) antagonist. In animal studies, good exposure of AMG 517 is seen from a 10% (w/v) Pluronic F108 in OraPlus suspension. Investigation of the suspension formulation revealed that AMG 517 forms a co-crystal with sorbic acid, a preservative in OraPlus. This co-crystal of AMG 517 was isolated by coslurrying AMG 517 and sorbic acid; studied by DSC and XRD; and identified by solution NMR, TGA, and HPLC to be a 1:1 association of AMG 517 and sorbic acid. Single crystal structure analysis revealed a 1:1 co-crystal of AMG 517 and sorbic acid, held together by two hydrogen bonds and other noncovalent, nonionic forces. The co-crystal has better aqueous solubility initially as compared to AMG 517 free base but does revert back to a form of the free base hydrate during prolonged slurry in FaSIF (fasted simulated intestinal fluid). Pharmacokinetic evaluation of the co-crystal in rats using 10% (w/v) Pluronic F108 in OraPlus suspensions revealed that a 30 mg/kg dose in suspension had comparable exposure to a 500 mg/kg dose of the free base.

[1]  Michael J. Zaworotko,et al.  Crystal engineering of the composition of pharmaceutical phases. Do pharmaceutical co-crystals represent a new path to improved medicines? , 2004 .

[2]  Matthew L Peterson,et al.  Celecoxib:nicotinamide dissociation: using excipients to capture the cocrystal's potential. , 2007, Molecular pharmaceutics.

[3]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings , 1997 .

[4]  Peddy Vishweshwar,et al.  Pharmaceutical co-crystals. , 2006, Journal of pharmaceutical sciences.

[5]  Olga Kennard,et al.  Systematic analysis of structural data as a research technique in organic chemistry , 1983 .

[6]  K. Higaki,et al.  Prediction of the Plasma Concentration Profiles of Orally Administered Drugs in Rats on the Basis of Gastrointestinal Transit Kinetics and Absorbability , 1997, The Journal of pharmacy and pharmacology.

[7]  Julian L. Baker,et al.  XCVI.—Halogen derivatives of quinone. Part III. Derivatives of quinhydrone , 1893 .

[8]  Orn Almarsson,et al.  Crystal engineering of the composition of pharmaceutical phases. Do pharmaceutical co-crystals represent a new path to improved medicines? , 2003, Chemical communications.

[9]  Aeri Park,et al.  Use of a Glutaric Acid Cocrystal to Improve Oral Bioavailability of a Low Solubility API , 2006, Pharmaceutical Research.

[10]  K. Tanaka,et al.  Solvent-free organic synthesis. , 2000, Chemical reviews.

[11]  William Jones,et al.  Solvent-drop grinding: green polymorph control of cocrystallisation. , 2004, Chemical communications.

[12]  I. Paul,et al.  CPMAS (cross-polarization magic angle spinning) carbon-13 NMR spectra of quinones, hydroquinones, and their complexes. Use of CMR to follow a reaction in the solid state , 1985 .

[13]  A. Basbaum,et al.  Molecular mechanisms of nociception , 2001, Nature.

[14]  Alex M. Chen,et al.  Development of a pharmaceutical cocrystal of a monophosphate salt with phosphoric acid. , 2007, Chemical communications.

[15]  N. Chen,et al.  Novel vanilloid receptor-1 antagonists: 2. Structure-activity relationships of 4-oxopyrimidines leading to the selection of a clinical candidate. , 2007, Journal of medicinal chemistry.

[16]  I. Paul,et al.  Interconversion by hydrogen transfer of unsymmetrically substituted quinhydrones in the solid state. Crystal structure of the 1:2 complex of 2,5-dimethylquinone with hydroquinone , 1984 .

[17]  L. D. Taylor,et al.  Molecular Self-Assembly in the Solid State. The Combined Use of Solid-State NMR and Differential Scanning Calorimetry for the Determination of Phase Constitution , 1994 .

[18]  J. McMahon,et al.  Crystal engineering of the composition of pharmaceutical phases. , 2003, Chemical communications.

[19]  Orn Almarsson,et al.  Performance comparison of a co-crystal of carbamazepine with marketed product. , 2007, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[20]  Jeanette T. Dunlap,et al.  Crystal engineering approach to forming cocrystals of amine hydrochlorides with organic acids. Molecular complexes of fluoxetine hydrochloride with benzoic, succinic, and fumaric acids. , 2004, Journal of the American Chemical Society.

[21]  J. McMahon,et al.  Crystal engineering of the composition of pharmaceutical phases. 3. Primary amide supramolecular heterosynthons and their role in the design of pharmaceutical co-crystals , 2005 .

[22]  Orn Almarsson,et al.  Crystal engineering of novel cocrystals of a triazole drug with 1,4-dicarboxylic acids. , 2003, Journal of the American Chemical Society.

[23]  Jack D. Dunitz,et al.  Crystal and co-crystal: A second opinion , 2003 .

[24]  I. Paul,et al.  Solid-state formation of quinhydrones from their components: use of solid-solid reactions to prepare compounds not accessible from solution , 1984 .

[25]  A. Medek,et al.  Solid-state acid-base interactions in complexes of heterocyclic bases with dicarboxylic acids: crystallography, hydrogen bond analysis, and 15N NMR spectroscopy. , 2006, Journal of the American Chemical Society.

[26]  Vinod P. Shah,et al.  The Bioinequivalence of Carbamazepine Tablets with a History of Clinical Failures , 1992, Pharmaceutical Research.

[27]  Michael J. Zaworotko,et al.  Superstructural diversity in two dimensions: crystal engineering of laminated solids , 2001 .

[28]  Michael J Cima,et al.  High-throughput crystallization: polymorphs, salts, co-crystals and solvates of pharmaceutical solids. , 2004, Advanced drug delivery reviews.

[29]  W. Tong,et al.  In situ salt screening--a useful technique for discovery support and preformulation studies. , 1998, Pharmaceutical development and technology.

[30]  W. H. Pirkle,et al.  Chiral recognition in the solid state : crystallographically characterized diastereomeric co-crystals between a synthetic chiral selector (Whelk-O1) and a representative chiral analyte , 2005 .